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Abstract: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western
countries. Its etiology is largely unknown but increasing incidence rates observed worldwide suggest
that lifestyle and environmental factors such as diet might play a role in the development of CLL.
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Hence, we hypothesized that the consumption of ultra-processed food and drinks (UPF) might be
associated with CLL. Data from a Spanish population-based case-control study (MCC-Spain study)
including 230 CLL cases (recruited within three years of diagnosis) and 1634 population-based
controls were used. The usual diet during the previous year was collected through a validated
food frequency questionnaire and food and drink consumption was categorized using the NOVA
classification scheme. Logistic regression models adjusted for potential confounders were used.
Overall, no association was reported between the consumption of UPF and CLL cases (OR per
each 10% increase of the relative contribution of UPF to total dietary intake = 1.09 (95% CI: 0.94;
1.25)), independently of the Rai stage at diagnosis. However, when analyses were restricted to cases
diagnosed within <1 year (incident), each 10% increment in the consumption of UPF was associated
with a 22% higher odds ratio of CLL (95% CI: 1.02, 1.47) suggesting that the overall results might be
affected by the inclusion of prevalent cases, who might have changed their dietary habits after cancer
diagnosis. Given the low number of cases in the subgroup analyses and multiple tests performed,
chance findings cannot totally be ruled out. Nonetheless, positive associations found in CLL incident
cases merit further research, ideally in well-powered studies with a prospective design.
Keywords: chronic lymphocytic leukemia; cancer; NOVA classification; ultra-processed food; case-
control study
1. Introduction
Chronic lymphocytic leukemia (CLL), a subtype of non-Hodgkin lymphoma (NHL),
is the most common leukemia in adults in Western countries with an incidence rate of
5 per 100,000 person-years in Europe [1]. The disease, characterized by an abnormal
accumulation of B-lymphocytes in blood, bone marrow and/or lymphoid tissues, typically
occurs in the elderly and shows a highly heterogeneous clinical course. While the majority
of patients live for decades without being treated and die from other causes, others show
a rapidly aggressive course and premature death [2]. In line with other hematological
neoplasms, the etiology of CLL is largely unknown with a few well-established risk factors
including increasing age, male sex, being Caucasian and a familial history of hematological
neoplasms and several suggestive associations yet to be confirmed [3]. However, the high
incidence of CLL in Western regions [4], the increasing CLL incidence rates across the
world [5] and the change in CLL incidence patterns with acculturation as seen in higher
incidence rates among Asian US born than Asian foreign born [6,7] suggest that lifestyle
and environmental factors may also play an important role CLL etiology.
With regard to dietary exposures, the 2007 report by the World Cancer Research
Fund/American Institute for Cancer Research (WCRF/AICR) [8] pointed out a suggestive
inverse association between NHL and the consumption of vegetables, fruit and alcoholic
beverages and a positive association with meat, total fat, body fatness and dairy. Recent
meta-analyses further support these associations [9–13] but data are still inconclusive,
particularly for specific NHL subtypes. Specifically, in CLL, evidence regarding dietary
exposures and the risk of CLL, which mainly arises from studies assessing single food
items [14], is inconsistent. However, the few studies that have examined dietary pat-
terns have reported an association between an adherence to a Western-like diet with
NHL [15] and CLL [14]. Whether the presence of ultra-processed food and drinks (UPF) in
a western dietary pattern (typically high in saturated fats, processed meat, refined grains,
sweets, caloric drinks and convenience foods) is contributing to the associations found is
not known.
According to the NOVA classification [16], UPF are industrial formulations typically
with five of more ingredients made mostly or entirely from substances derived from foods
and additives. Following multiple biological, physical and chemical processes, these ulti-
mate products are conceived to be safe, highly palatable and affordable. However, other
less desirable properties [17,18] including their poor nutritional composition (i.e., high
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amounts of saturated fats, refined starches, free sugars and salts), the potential presence
of components derived from food processing (i.e., heterocycle amines, acrylamide or aro-
matic polycyclic hydrocarbons) or packaging (i.e., bisphenol A) might have a deleterious
effect on human health [17]. Indeed, cumulative evidence from epidemiological studies
points to an association between the consumption of UPF and obesity [19], cardiovascular
disease [20], mortality [21–23] and, more recently, cancer [24,25]. Regarding the latter, a
French prospective study conducted in 104,980 participants reported an increased risk
of developing cancer and, more specifically, breast cancer [24]. Lately, in a large Span-
ish multicase-control study (MCC-Spain) including cases of colorectal (n = 1852), breast
(n = 1486) and prostate cancer (n = 953), the consumption of UPF was associated with
colorectal cancer [25]. However, to date, no study has assessed their potential impact on
hematological neoplasms.
Considering this, the aim of the present study was to evaluate whether the consump-
tion of UPF was associated with CLL in the MCC-Spain study.
2. Materials and Methods
2.1. Study Population
MCC-Spain (http://www.mccspain.org) (accessed on 11 January 2021) was a population-
based multicenter case-control study conducted in Spain in 2008–2013 [26]. Adult CLL cases
were recruited in eleven hospitals from five Spanish provinces (i.e., Asturias, Barcelona,
Cantabria, Girona and Granada). The controls were randomly selected from primary health
centers and were frequency matched by sex, geographical area and age. The participation
rates were 87% in cases and 53% in controls, which varied by region. After excluding
subjects with no dietary data, implausible energy intakes <750 or >4500 kcal/day and CLL
cases recruited more than three years after diagnosis, a total of 1634 controls and 230 CLL
cases were included (Supplementary Material, Flow Chart) in the present study.
2.2. Outcome Definition
Both cases of CLL and small lymphocytic lymphoma (SLL) were recruited, as they
are considered to be the same underlying disease [27]. All diagnoses were histologically
and morphologically confirmed and fulfilled the 2008 WHO criteria [27]. CLL/SLL cases
were identified from March 2010 to November 2013 in hospitals from five Spanish regions
(i.e., Barcelona, Girona, Granada, Asturias and Cantabria). Given the indolent course of
the disease, newly diagnosed cases as well as patients with a CLL/SLL diagnosis prior
to the start of the study (up to three years) were included. Thus, separate analyses for
incident cases (time from diagnosis to interview <1 year, n = 97) and prevalent cases (time
from diagnosis to interview 1–3 years, n = 133) were performed as sensitivity analyses. In
addition, the disease severity was assessed using the Rai staging system obtained from
medical records and verified by local hematologists. The cases were then categorized into a
low-risk category (Rai 0, n = 138) and an intermediate/high-risk category (Rai I–IV, n = 81).
2.3. Data Collection
Trained personnel collected data on socio-demographic factors, lifestyle and per-
sonal/family medical history through face-to-face interviews using a computerized ques-
tionnaire. Dietary data were collected using a 140 item semi-quantitative food frequency
questionnaire (FFQ), which assessed the usual food intake during the previous year. The
FFQ was an adapted version of a Spanish validated FFQ, modified to include several
Spanish regional foods [28]. The FFQ was self-administered and returned by mail or filled
out in face-to-face interviews. The nutrient intake was calculated using Spanish food
composition [29]. Cross-check questions on aggregated food group intakes were used to
reduce the misreporting of food groups with a large number of items and to adjust the
frequency of food consumption [30].
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2.4. Exposure: UPF
Food and drink items of the FFQ were categorized into one of the four groups in
NOVA, a food classification system based on the extent and purpose of industrial food
processing [25]. For several items, not enough information was available in the FFQ
to unequivocally classify them into one of the four NOVA categories. In such cases,
a consensus was reached based on the food composition table used [31], the labels of
the products and information of the usual consumption from household consumption
databases [32]. The detailed description of these variables and the assumptions made are
provided in the Supplementary Material, Table S1. This study primarily focused on group 4
of the NOVA classification, which includes industrial formulations that have usually added
industrial ingredients such as hydrogenated oils, flavors or emulsifiers and contain little or
no whole foods (e.g., sweet or savory packaged snacks, sweetened beverages and ready to
eat foods). Following previous studies [24,25], for each individual the consumption of all
items included in each NOVA group (expressed in daily grams) was added and expressed
as a percentage of the total dietary intake (daily g within the NOVA category/total daily
g, multiplied by 100). This variable was further categorized into low, medium and high
consumption according to sex-specific tertiles in the control group.
2.5. Statistical Analyses
We performed descriptive analyses of anthropometric, socio-demographic and lifestyle
characteristics. The differences between cases and controls and across tertiles of the con-
sumption of UPF were assessed using a Student’s t-test (or ANOVA test, when appropriate)
and a Pearson chi-squared test.
We used multivariable logistic regression models to evaluate the association between
UPF and CLL. Odds ratios (OR) and 95% confidence intervals (CI) were calculated. The UPF
were analyzed as a continuous variable (per 10% increment) and as a categorical variable
(low, medium, high consumption). The first tertile (low consumption) was considered to be
a reference category. P-value for the trend was calculated including the categorical variable
as a continuous ordinal (scored from 1 to 3) in our models.
Two models with two levels of adjustment were used. The basic model (model 1)
included as covariates age, sex, educational level and province. The multiple adjusted
model (model 2) further included a family history of hematologic malignancies, having ever
worked in farming or agriculture, energy intake, body mass index, ethanol intake, physical
activity in the last ten years up to two years before diagnosis and smoking status. Missing
values in the categorical variables were coded as a separate category (Table 1). Model 2
was also run after stratification according to a series of variables that might influence the
association between UPF and CLL (i.e., age, sex, smoking and alcohol consumption). The
effect modifications were explored by modelling interaction terms between those variables
and the (continuous) consumption of UPF and tested using log-likelihood ratio tests.
In line with previous studies on UPF [24,25], we performed complementary analyses
by further adjusting model 2 for dietary factors that could act as potential confounders
of the association: energy density (kcal), fiber intake (g/day), sugar intake (% of total
energy intake), saturated fatty acid intake (% of total energy intake) and fruit and vegetable
consumption (g/day).
As we assessed the usual diet during the previous year, in cases interviewed within
≥1 year from diagnosis, we captured a post-diagnosis diet. To ensure that potential dietary
changes or survival bias might not be influencing our results, we performed stratified
analyses by time from diagnosis to interview (<1 year, i.e., incident cases and ≥1 year, i.e.,
prevalent cases). Likewise, we performed stratified analyses by the severity of disease (Rai
0 vs. Rai 1–4). Finally, sensitivity analyses excluding cases treated before the interview
(n = 34) were performed.
All analyses were performed using free software R (R version 3.5.2) [33] and the
statistical significance was set at two-sided p < 0.05.
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Table 1. Baseline characteristics of controls and cases in the MCC-Spain study.
Controls (n = 1634) Cases (n = 230) p-Value 2
Consumption of UPF (g/day), mean (SD) 277.3 (280.8) 298.9 (335.7) 0.353
Consumption of UPF (%) 1, mean (SD) 13.8 (10.6) 14.4 (11.6) 0.466
Province, n (%) <0.001
Barcelona 897 (54.9) 148 (64.3)
Asturias 211 (12.9) 29 (12.6)
Cantabria 308 (18.8) 7 (3)
Granada 146 (8.9) 22 (9.6)
Girona 72 (4.4) 24 (10.4)
Age (years), mean (SD) 63.9 (10.8) 65.7 (10.1) 0.01
Sex, n (%) 0.07
Male 944 (57.8) 148 (64.3)
Female 690 (42.2) 82 (35.7)
Education, n (%) 0.718
Primary 871 (53.3) 129 (56)
Secondary 476 (29.1) 62 (27)
University 287 (17.6) 39 (17)
Body mass index 3 (kg/m2), mean (SD) 26.9 (4.4) 27.3 (4.2) 0.195
Energy intake (kcal/day), mean (SD) 1902.5 (585.9) 1972.4 (615.7) 0.106
Alcohol consumption, median (IQR) 5.6 (0.8–16.5) 5.1 (0.4–11.6) 0.007
Smoking status, n (%) 0.468
Never 711 (43.5) 93 (40.4)
Former 628 (38.4) 98 (42.6)
Current 290 (17.7) 37 (16.1)
Unknown 5 (0.3) 2 (0.9)
Physical activity 4, n (%) 0.720
Inactive 669 (40.9) 87 (37.8)
Moderately active 224 (13.7) 32 (13.9)
Active 194 (11.9) 29 (12.6)
Very active 510 (31.2) 80 (34.8)
Unknown 37 (2.3) 2 (0.9)
Ever worked in farming or agriculture,
n (%) <0.001
No 1301 (79.6) 151 (65.7)
Yes 330 (20.2) 78 (33.9)
Unknown 3 (0.2) 1 (0.4)
Family history of hematological
malignancy, n (%)
No 1445 (88.4) 193 (83.9) <0.001
Yes 81 (5) 26 (11.3)
Unknown 108 (6.6) 11 (4.8)
Rai stage, n (%)
0 - 138 (60.0)
1–4 - 88 (38.3)
Unknown - 4 (1.7)
UPF, ultra-processed food and drinks (based on group 4 of the NOVA classification); SD, standard deviation; IQR,
interquartile range. 1 Calculated as daily g of UPF/total daily g, multiplied by 100. 2 p-value for heterogeneity
calculated with the Student’s t-test for continuous variables and with the chi-squared test for categorical variables.
Missing values were excluded from these tests. 3 There were 76 individuals (8 cases, 68 controls) with missing
information on body mass index. 4 Physical activity in the last 10 years up to 2 years before diagnosis measured
in METs/week: inactive (0), low (0.1–8), moderate (8–15.9) and very active (≥16). In bold: p-value < 0.05.
3. Results
The distribution of baseline characteristics between cases and controls is shown in
Table 1. Compared with the controls, the cases were slightly older, had a lower alcohol
intake and were more likely to have a familial history of hematological neoplasms and
to have ever worked in farming/agriculture. In the controls, on average, the relative
contribution of each NOVA group to the total food intake was: group 4: 13.8% (SD: 10.6),
group 3: 17.5% (SD: 11.0), group 2: 1.6% (SD: 1.1) and group 1: 67.0% (SD: 13.8). Beverages,
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sugary products, ready to eat products and processed meats were the UPF most frequently
consumed among group 4 (Supplementary Material, Figure S1).
The distribution of control characteristics according to the level of the consumption
of UPF is displayed in Table 2. Those participants in tertile 3 of the consumption of UPF
(relative contribution of UPF to total food intake = 25.7% (SD 9.6%)) were on average
younger, with a higher energy intake, smokers, less physically active and less likely to have
worked in agriculture (all p-values < 0.05). No differences across the different levels of
exposure were observed for other lifestyle factors. The same analyses, restricted to cases,
are provided in the Supplementary Material, Table S2.
Table 2. Characteristics of participants in the control group according to the consumption of ultra-processed food (NOVA
classification, group 4) in the MCC-Spain study.
Consumption of Ultra-Processed Food and Drinks 1
Low (n = 546) Medium (n = 546) High (n = 542) p-Value 3
Consumption of UPF (%) 2, mean (SD) 4.5 (1.9) 11.3 (2.3) 25.7 (9.6) <0.001
In men, mean (min–max) 4.8 (0.0–7.7) 11.3 (7.7–15.6) 25.3 (15.7–69.24)
In women, mean (min–max) 4.2 (0.0–7.5) 11.4 (7.5–16.0) 26.4 (16.1–66.1)
Province, n (%) 0.018
Barcelona 289 (52.9) 300 (54.9) 308 (56.8)
Asturias 85 (15.6) 71 (13) 55 (10.1)
Cantabria 92 (16.8) 107 (19.6) 109 (20.1)
Granada 63 (11.5) 39 (7.1) 44 (8.1)
Girona 17 (3.1) 29 (5.3) 26 (4.8)
Age (years), mean (SD) 67.2 (9.1) 63.6 (10.7) 60.9 (11.6) <0.001
Sex, n (%) 0.926
Male 316 (57.9) 312 (57.1) 316 (58.3)
Female 230 (42.1) 234 (42.9) 226 (41.7)
Education, n (%) 0.171
Primary 310 (56.8) 294 (53.8) 267 (49.3)
Secondary 149 (27.3) 155 (28.4) 172 (31.7)
University 87 (15.9) 97 (17.8) 103 (19)
Body mass index 4 (kg/m2), mean (SD) 26.9 (4.2) 26.8 (4.4) 27.0 (4.5) 0.884
Energy intake (kcal/day), mean (SD) 1723.3 (495.0) 1925.8 (543.3) 2059.5 (659.0) <0.001
Alcohol consumption, median (IQR) 6.4 (0.6–16.9) 5.1 (0.6–18.6) 5.2 (0.8–15.0) 0.214
Smoking status, n (%) <0.001
Never 268 (49.1) 222 (40.7) 221 (40.8)
Former 215 (39.4) 216 (39.6) 197 (36.3)
Current 61 (11.2) 108 (19.8) 121 (22.3)
Unknown 2 (0.4) 0 0
Physical activity 5, n (%) 0.003
Inactive 211 (38.6) 211 (38.6) 247 (45.6)
Moderately active 63 (11.5) 86 (15.8) 75 (13.8)
Active 81 (14.8) 53 (9.7) 60 (11.1)
Very active 184 (33.7) 182 (33.3) 144 (26.6)
Unknown 7 (1.3) 14 (2.6) 16 (3)
Ever worked in farming or agriculture, n (%) <0.001
No 404 (74) 439 (80.4) 458 (84.5)
Yes 142 (26) 107 (19.6) 81 (14.9)
Unknown 0 0 3 (0.6)
Family history of hematological malignancy, n (%) 0.948
No 483 (88.5) 479 (87.7) 483 (89.1)
Yes 27 (4.9) 30 (5.5) 24 (4.4)
Unknown 36 (6.6) 37 (6.8) 35 (6.5)
UPF, ultra-processed food and drinks (based on group 4 of the NOVA classification); SD, standard deviation; IQR, interquartile range.
1 Categories based on sex-specific tertiles of the consumption of ultra-processed food and drinks. 2 Calculated as daily g of UPF/total
daily g, multiplied by 100. 3 p-value for heterogeneity calculated with the ANOVA for continuous variables and with the chi-squared test
for categorical variables. Missing values were excluded from these tests. 4 There were 68 controls with missing information on body mass
index. 5 Physical activity in the last 10 years up to 2 years before diagnosis measured in METs/week: inactive (0), low (0.1–8), moderate
(8–15.9) and very active (≥16). In bold: p-value < 0.05.
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The consumption of UPF was not associated with overall CLL both when modelled
as a categorical (ORhigh.vs.low 1.09 (95% CI 0.74; 1.60), p-trend = 0.665) or as a continuous
variable (OR per each 10% increment in the consumption of UPF = 1.09 (95% CI: 0.94;
1.25)) (Table 3). The findings were similar regardless of the disease severity (Rai stage)
(Table 3) and did not materially change when excluding cases treated before the interview
(n = 34, data not shown). However, the results differed markedly between the incident and
prevalent cases (Table 3). In the incident cases, each 10% increment in the consumption of
UPF was associated with a 22% higher odds ratio of having CLL (95% CI: 1.02, 1.47). By
contrast, null associations were reported in prevalent cases.
Table 3. Association between the consumption of ultra-processed food (NOVA classification, group 4) and chronic
lymphocytic leukemia overall by Rai stage and the time from diagnosis to interview in the MCC-Spain study.












OR (95% CI) p-Het
2
Total -
320/1634 Model 1 1 1.02 (0.72; 1.45) 1.12 (0.79; 1.59) 0.54 1.09 (0.96; 1.24)
222/1566 Model 2 1 1.00 (0.69; 1.45) 1.09 (0.74; 1.60) 0.67 1.09 (0.94; 1.25)
Rai stage at diagnosis 3 0.31
0 138/1634 Model 1 1 1.00 (0.65; 1.55) 1.02 (0.66; 1.60) 0.92 1.04 (0.88; 1.24)
131/1566 Model 2 1 1.03 (0.65; 1.63) 1.05 (0.65; 1.71) 0.83 1.05 (0.87; 1.25)
1–4 88/1634 Model 1 1 1.14 (0.65; 1.99) 1.42 (0.83; 2.46) 0.20 1.19 (0.99; 1.43)
87/1566 Model 2 1 1.02 (0.57; 1.81) 1.24/0.69; 2.22) 0.46 1.16 (0.95; 1.42)




97/1634 Model 1 1 1.30 (0.77; 2.20) 1.46 (0.86; 2.47) 0.16 1.23 (1.03; 1.46)





133/1634 Model 1 1 0.87 (0.56; 1.36) 0.92 (0.58; 1.44) 0.70 0.97 (0.81; 1.17)
128/1566 Model 2 1 0.79 (0.50; 1.27) 0.84 (0.52; 1.37) 0.49 0.95 (0.78; 1.16)
N, number; OR, odds ratio; CI, confidence interval; P-het: p-values for heterogeneity.1 Categories based on sex-specific tertiles of the
consumption of ultra-processed food and drinks. 2 Test of heterogeneity based on case-case analyses, assessed using the continuous UPF
variable and the model 2 level of adjustment. 3 In four CLL cases, the RAI stage was not available hence they were excluded from the
analyses by RAI stage. Model 1: logistic regression model adjusted for age, sex, province and educational level. Model 2: model 1 further
adjusted for family history of hematological neoplasms, ever worked in farming, physical activity, energy intake, ethanol intake and
smoking status. In bold: p-value < 0.05.
Figure 1 shows the association between UPF (per 10% increment) and CLL using
model 2 further adjusted for several nutritional variables that could act as confounders or
mediators of the association. The association between the consumption of UPF and CLL in
incident cases remained when dietary fiber, saturated fat, simple carbohydrates, energy
density and fruit and vegetables were included in the adjustment while the results for all
CLLs continued to be null.
In the Supplementary Material, Table S2, the effect modification and stratified analyses
by age, sex and lifestyle factors are shown. All p-values for interaction were non-statistically
significant, indicative of no effect-measure modification. In stratified analyses, the con-
sumption of UPF was significantly associated with CLL (both in total and incident cases)
in women and non-smokers.
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4. Discussion
In this study, we did not find a clear pattern of association between UPF and CLL
overall and by Rai stage at diagnosis. However, in analyses restricted to incident cases,
each 10% increment in the consumption of UPF was associated with a 22% higher odds
ratio of CLL, suggesting that such exposure might be associated with CLL.
Since the development of the NOVA classification [16], numerous observational stud-
ies have associated the consumption of UPF with mortality [21–23] and several non-
communicable diseases such as obesity [19] and cardiovascular disease [20]. In 2018,
the results from the French NutriNet-Santé prospective cohort pointed, for the first time,
to a link between the consumption of such items and cancer, particularly overall and
breast cancer but not for colorectal or prostate cancers [24]. Such analyses were latterly
replicated in the MCC-Spain study, which revealed an association with colorectal cancer
(ORT1vs.T3 = 1.30, 95% CI 1.11, 1.51) and null associations for breast or prostate cancers [25].
Our results, conducted in the same study, did not conclusively support an association for
CLL. However, we noted a suggestive association in incident cases (n = 94, OR: 1.22, 95%
CI: 1.02, 1.47), in contrast to those with a longer time from diagnosis to interview (n = 128,
OR: 0.95, 95% CI: 0.78, 1.16). Although CLL is typically an indolent disease, we cannot
totally rule out that the inclusion of prevalent cases might have attenuated our estimates
due to survival bias or, furthermore, dietary changes after diagnosis. Thus, the results in
incident cases point to a potential association between the consumption of UPF and CLL,
which should be clarified in further studies ideally with a prospective design and more
statistical power.
Several hypotheses have been suggested to explain the association between the con-
sumption of UPF and cancer risk. One relates to the poorer nutritional quality of diets rich
in processed foods, which tend to be rich in sugars, fats, salt and excessive energy [17,34].
In our study, however, the association of UPF with CLL in incident cases remained statisti-
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cally significant after the adjustment for these dietary factors, suggesting, in line with other
studies [24], the involvement of other components (e.g., additives or bioactive compounds
derived from processing/packaging) beyond “nutritional quality”. Overall, mediation
studies are needed to better understand the relative role of nutritional composition, addi-
tives and neoformed contaminants in this relationship.
Traditionally, Spain has been a country with a relatively low energy contribution
of UPF in comparison with other Western regions such as the United States (2007–2012,
58.5%) [35], UK (2008–2012, 53%) [36] and France (2009–2014, 35.9%) [37]. According
to previous data from the Data Food Networking Database repository (2000) [38] or a
national prospective cohort (2008–2010) [21], UPF account for 20–25% of the total dietary
calories in Spain. Thus, in our study, we dealt with an overall lower exposure to UPF
with less contrast between the extreme categories, which may have attenuated our risk
estimates. Thus, further analyses in forthcoming studies including younger subjects or
settled in countries with greater levels of the consumption of UPF are warranted to confirm
our findings.
Several limitations must be acknowledged when interpreting our results. Firstly,
case-control studies are prone to be affected by recall and selection biases. Measurement
errors in the estimation of dietary intake are also likely although we used a previously
validated FFQ for Spanish populations. In addition, several food items could not be
unequivocally classified into one of the four NOVA groups, given that our FFQ collected
limited information regarding food processing (e.g., place of meals and product brand) (see
Supplementary Material, Table S1). In such cases, we used information on food composition
in Spain to classify such food items and, thus, a degree of misclassification is expectable.
The parameters used to construct our consumption score for UPF were based on the food
intake during the previous year to recruitment. We assumed that the measured dietary
exposure at the baseline actually reflected the eating habits of subjects during adulthood.
However, if dietary changes had occurred during that period, we might have modelled
a “recent exposure” that might not be associated with CLL lymphomagenesis in which
risk factors are expected to take decades to contribute to disease development. This is
particularly relevant for prevalent cases in case they changed their habitual diet after cancer
diagnosis. We may have been limited by a lack of statistical power to detect significant
associations when running subgroup analyses. In addition, these associations should be
interpreted in the context of multiple comparisons and the possibility of chance findings.
Finally, although we adjusted for a range of potential confounders, residual confounding
cannot be totally ruled out. In particular, we lacked the data of several conditions such as
autoimmune diseases and allergies that have been consistently associated with CLL [3]
and that should ideally be considered in future studies.
5. Conclusions
Findings from this Spanish population-based case-control study did not conclusively
support an association between the consumption of UPF and CLL; however, the results
may be biased due to the inclusion of prevalent cases. The association reported in the
analyses restricted to incident cases pointed to a potential role of UPF in CLL. Further
studies, ideally with a prospective design and more statistical power, are required to
confirm these findings.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/ijerph18105457/s1, Flow chart; Table S1: Classification of foods according to the NOVA
definition in the MCC-Spain study; Figure S1: Relative contribution of each food group to the
consumption of ultra-processed food and drinks (NOVA classification, group 4) in controls of the
MCC-Spain study; Table S2: Association between the consumption of ultra-processed food and drinks
(NOVA classification, group 4) and chronic lymphocytic leukemia stratified by sex, age, smoking
status and alcohol consumption in the MCC-Spain study.
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